Q4 2024 Tenon Medical Inc Earnings Call Transcript
Key Points
- Tenon Medical Inc (TNON) achieved a 12% revenue growth for the full year 2024, reaching $3.3 million.
- Gross margin improved by 10 percentage points to 52% for the year, indicating better profitability.
- The company completed the Alpha clinical review of its second-generation Catamaran SE platform, which was well-received by physicians.
- Tenon Medical Inc (TNON) received three new US patents related to its Catamaran portfolio, enhancing its competitive position.
- The company has a strong cash position with $6.5 million in cash and cash equivalents as of December 31, 2024, and no outstanding debt.
- Fourth-quarter revenue declined by 4.7% compared to the prior year, primarily due to reimbursement pre-authorization headwinds.
- Gross profit in the fourth quarter of 2024 decreased to 46% of revenue from 69% in the same quarter of 2023.
- Operating expenses for the year remained high at $15.5 million, despite a decrease from the previous year.
- The company reported a net loss of $13.7 million for the year ended December 31, 2024.
- Reimbursement and pre-authorization delays continue to impact the number of surgical procedures performed.
Greetings and welcome to the Tana Medical fourth quarter in full year 2024 financial results and corporated conference call.
As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer.
Mr. Foster and Mr. Williamson will present results of operations for the 4th quarter and full year ending December 31, 2024 and provide a corporate update.
A press release detailing these results was released today and is available on the investor relations section of our company's website www.enonmed.com.
Before we begin the formal presentation, I'd like to remind everyone that statements made on the call and webcast may include predictions, estimates, and other information that may be considered forward-looking.
What these forward-looking statements represent our current judgment on what the future holds, they are subject to risk and uncertainties that could cause actual results that differ materially. You
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
